Roivant Sciences Ltd.
ROIV
Clasificación en acciones
#979
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Precio por acción
$33.73
Última sincronización: 2026-07-31
Capitalización bursátil
$24.37B
Cambio (1 día)
-2.28%
Cambio (1 año)
90.15%
País
GB
Comercio Roivant Sciences Ltd. (ROIV)
Categoría
Healthcare
Ganancias de Roivant Sciences Ltd. (ROIV)
Ganancias en Jun 2026 TTM: $-289.88M
Secondo gli ultimi rapporti finanziari di Roivant Sciences Ltd., gli utili attuali della società sono $-289.88M. Nel 2024, la società ha registrato un utile di $4.57B, un aumento con respecto a agli utili del 2023, che erano di $-1.22B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Roivant Sciences Ltd. desde 2020 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-289.88M | -57.47% |
| 2025 | $-681.59M | -114.92% |
| 2024 | $4.57B | -472.94% |
| 2023 | $-1.22B | 32.59% |
| 2022 | $-923.75M | 2.80% |
| 2021 | $-898.55M | 60.17% |
| 2020 | $-560.99M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -1,919.68% |
US
|
|
| $-3.09B | 964.92% |
US
|
|
| $-4.02B | 1,285.47% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -772.92% |
NL
|
